Mechanism of Action: Nintedanib (BIBF 1120)
Nintedanib (also known as Vargatef and BIBF 1120) is an oxindole-based, orally-available triple kinase inhibitor targeting the angiogenesis factors VEGF, PDGF, and FGF.
Nintedanib (also known as Vargatef and BIBF 1120) is an oxindole-based, orally-available triple kinase inhibitor targeting the angiogenesis factors vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblast growth factor (FGF).
Recent Videos
Related Content
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024Podcast
In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
